Biosig Technologies (NASDAQ:STEX) Rating Lowered to “Strong Sell” at Wall Street Zen

Biosig Technologies (NASDAQ:STEX) was downgraded by Wall Street Zen from a “hold” rating to a “strong sell” rating in a research note issued to investors on Sunday.

Separately, Weiss Ratings assumed coverage on Biosig Technologies in a research report on Friday, January 23rd. They issued a “sell (d-)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Biosig Technologies currently has a consensus rating of “Sell”.

Biosig Technologies Price Performance

STEX opened at $1.16 on Friday. Biosig Technologies has a 1-year low of $0.40 and a 1-year high of $14.11. The business has a 50-day moving average of $2.24. The company has a market cap of $207.08 million, a P/E ratio of -0.12 and a beta of 1.90.

Biosig Technologies (NASDAQ:STEX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($8.23) earnings per share for the quarter.

Insider Transactions at Biosig Technologies

In other Biosig Technologies news, Director Morgan Lee Lekstrom purchased 41,000 shares of the firm’s stock in a transaction dated Friday, January 23rd. The stock was acquired at an average cost of $3.13 per share, with a total value of $128,330.00. Following the acquisition, the director owned 48,000 shares of the company’s stock, valued at approximately $150,240. This represents a 585.71% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CIO Mitchell Young Williams acquired 51,511 shares of the stock in a transaction that occurred on Friday, January 23rd. The shares were acquired at an average cost of $3.03 per share, with a total value of $156,078.33. Following the transaction, the executive owned 1,051,511 shares in the company, valued at approximately $3,186,078.33. The trade was a 5.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 1,267,011 shares of company stock worth $3,825,628. 52.73% of the stock is currently owned by insiders.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.